Apecotrep Shows Promise in Reducing Proteinuria in Primary FSGS in Phase 2 trial
In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 weeks in patients with primary focal segmental glomerulosclerosis (FSGS).…